Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 20/20 | 0.81 |
| ▸ | CASP7 | P55210 | 13/20 | 0.81 |
| ▸ | CASP1 | P29466 | 7/20 | 0.81 |
| ▸ | CASP9 | P55211 | 6/20 | 0.81 |
| ▸ | CASP10 | Q92851 | 2/20 | 0.64 |
| ▸ | CASP4 | P49662 | 2/20 | 0.52 |
| ▸ | CASP5 | P51878 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782013 | 0.96 | CASP3 (0.88) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL19015898 | 0.90 | CASP3 (1.00) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL19015845 | 0.90 | CASP3 (1.00) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL7970067 | 0.90 | CASP3 (1.00) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL18781766 | 0.87 | CASP3 (0.88) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL9962302 | 0.86 | CASP3 (0.81) | CASP3CASP7CASP1CASP9CASP10 | |
| SCHEMBL18782212 | 0.85 | CASP3 (0.90) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL18782319 | 0.83 | CASP3 (0.90) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL19015964 | 0.83 | CASP3 (0.85) | CASP3CASP7CASP1CASP9CASP4 | |
| SCHEMBL7976025 | 0.82 | CASP3 (0.83) | CASP3CASP7CASP1CASP9CASP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | GENESIS TECHNOLOGIES LIMITED (BB) | 2019-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167313-B2 | Selective caspase inhibitors and uses thereof | CASP1, CASP3, CASP5 | CASP3 2/4885CASP7 7/4885CASP1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.